Cullinan Therapeutics, Inc. (CGEM)

Market Cap	732.50M
Revenue (ttm)	n/a
Net Income (ttm)	-143.54M
Shares Out	58.23M
EPS (ttm)	-2.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	782,905
Open	12.99
Previous Close	13.10
Day's Range	12.50 - 13.52
52-Week Range	7.64 - 30.19
Beta	-0.12
Analysts	Strong Buy
Price Target	31.67 (+151.75%)
Earnings Date	Nov 7, 2024

About CGEM

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company’s lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 8, 2021
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: CGEM
• Website: https://cullinantherapeutics.com

Analyst Forecast

According to 7 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price forecast is $31.67, which is an increase of 151.75% from the latest price.

Price Target

$31.67

(151.75% upside)

Analyst Consensus: Strong Buy